nach oben

Erschienen in:

27.09.2018 | Gynecologic Oncology

Potential biomarker of circulating hsa-miR-1273g-3p level for detection of recurrent epithelial ovarian cancer

verfasst von: Tuba Günel, Ece Gumusoglu, Berkcan Dogan, Fatma Betül Ertem, Mohammad Kazem Hosseini, Nazife Cevik, Taylan Senol, Samet Topuz, Kilic Aydinli

Erschienen in: Archives of Gynecology and Obstetrics | Ausgabe 6/2018

Einloggen, um Zugang zu erhalten

Abstract

Purpose

Ovarian cancer (OC) is first gynaecologic cancer that causes women death and epithelial ovarian cancer (EOC) is the most lethal ovarian cancer type. While treatment is commonly successful, some cases (10–20%) show resistance to chemotherapy which is followed by recurrence. MicroRNA (miRNA) based diagnosis methods are slightly important for recurrent ovarian cancer diagnosis. We aimed to detect novel circulating miRNAs to be used as an early diagnosis and prediction tools for recurrent EOC.

Methods

In this study, recurrent EOC serum samples and healthy control serum samples were compared for miRNA expression analysis by microarray. Microarray results were analyzed by bioinformatics tools and differentially expressed hsa-miR-1273g-3p was obtained. After microarray analysis, differentially expressed hsa-miR-1273g-3p was validated by Real-Time PCR (RT-qPCR). The relation between target genes of hsa-miR-1273g-3p and ovarian cancer were examined by Pathway Studio^® (v.11.4.0.8).

Results

The expression of hsa-miR-1273g-3p was found to be significantly down-regulated by t test Bonferroni FWER corrected p < 0.05 and fold change > 2, in recurrence EOC compare with healthy controls groups. The RT-qPCR results confirmed that relative expressions of the serum hsa-miR-1273g-3p were significantly down-regulated in patients with recurrent EOC (p = 0.0275). Serum hsa-miR-1273g-3p levels could discriminate patients with recurrent EOC from healthy controls, with a power area under the curve (AUC) of 0.7.

Conclusion

This study suggested that hsa-miR-1273g-3p plays a significant role in regulation of related genes, which are TNF-alfa, COL1A1, MMP-2, MMP-9, with recurrent EOC outcome. hsa-miR-1273g-3p may be used as a prognostic marker for recurrent EOC after chemotherapy.

Nakamura K, Sawada K, Yoshimura A, Kinose Y, Nakatsuka E, Kimura T (2016) Clinical relevance of circulating cell-free microRNAs in ovarian cancer. Mol Cancer 15(1):48. https://doi.org/10.1186/s12943-016-0536-0 CrossRefPubMedPubMedCentral

Chong GO, Jeon HS, Han HS, Son JW, Lee YH, Hong DG, Lee YS, Cho YL (2015) Differential microRNA expression profiles in primary and recurrent epithelial ovarian cancer. Anticancer Res 35(5):2611–2617PubMed

Laios A, O’Toole S, Flavin R, Martin C, Kelly L, Ring M, Finn SP, Barrett C, Loda M, Gleeson N, D’Arcy T, McGuinness E, Sheils O, Sheppard B, Ol J (2008) Potential role of miR-9 and miR-223 in recurrent ovarian cancer. Mol Cancer 7:35. https://doi.org/10.1186/1476-4598-7-35 CrossRefPubMedPubMedCentral

Retamales-Ortega R, Oróstica L, Vera C, Cuevas P, Hernández A, Hurtado I, Vega M, Romero C (2017) Role of nerve growth factor (NGF) and miRNAs in epithelial ovarian cancer. Int J Mol Sci 18:507. https://doi.org/10.3390/ijms18030507 CrossRefPubMedCentral

Molasy M, Walczak A, Szaflik J, Szaflik JP, Majsterek I (2017) MicroRNAs in glaucoma and neurodegenerative diseases. J Hum Genet 62(1):105–112. https://doi.org/10.1038/jhg.2016.91 CrossRefPubMed

Barwari T, Joshi A, Mayr M (2016) MicroRNAs in cardiovascular disease. J Am Coll Cardiol 68(23):2577–2584. https://doi.org/10.1016/j.jacc.2016.09.945 CrossRefPubMed

Vienberg S, Geiger J, Madsen S, Dalgaard LT (2017) MicroRNAs in metabolism. Acta Physiol (Oxf) 219(2):346–361. https://doi.org/10.1111/apha.12681 CrossRef

Reddy KB (2015) MicroRNA (miRNA) in cancer. Cancer Cell Int 15:38. https://doi.org/10.1186/s12935-015-0185-1 CrossRefPubMedPubMedCentral

Ruan K, Fang X, Ouyang G (2009) MicroRNAs: novel regulators in the hallmarks of human cancer. Cancer Lett 285(2):116–126. https://doi.org/10.1016/j.canlet.2009.04.031 CrossRefPubMed

10.

Cochrane DR, Spoelstra NS, Howe EN, Nordeen SK, Richer JK (2009) MicroRNA-200c mitigates invasiveness and restores sensitivity to microtubule-targeting chemotherapeutic agents. Mol Cancer Ther 8(5):1055–1066. https://doi.org/10.1158/1535-7163.MCT-08-1046 CrossRefPubMedPubMedCentral

11.

James A, Daley CM, Greiner KA (2011) “Cutting” on cancer: attitudes about cancer spread and surgery among primary care patients in the USA. Soc Sci Med 73(11):1669–1673. https://doi.org/10.1016/j.socscimed.2011.09.017 CrossRefPubMedPubMedCentral

12.

Gumusoglu E, Gunel T (2018) The role of circulating biomarkers in the early diagnosis of ovarian cancer. Ovarian Cancer (in press)

13.

Chang B, Liu G, Xue F, Rosen DG, Xiao L, Wang X, Liu J (2009) ALDH1 expression correlates with favorable prognosis in ovarian cancers. Mod Pathol 22(6):817–823. https://doi.org/10.1038/modpathol.2009.35 CrossRefPubMedPubMedCentral

14.

Yang H, Kong W, He L, Zhao JJ, O’Donnell JD, Wang J, Wenham RM, Coppola D, Kruk PA, Nicosia SV, Cheng JQ (2008) MicroRNA expression profiling in human ovarian cancer: miR-214 induces cell survival and cisplatin resistance by targeting PTEN. Cancer Res 68(2):425–433. https://doi.org/10.1158/0008-5472.CAN-07-2488 CrossRefPubMed

15.

Ivashchenko A, Berillo O, Pyrkova A, Niyazova R (2014) Binding sites of miR-1273 family on the mRNA of target genes. Biomed Res Int 2014:620530. https://doi.org/10.1155/2014/620530 CrossRefPubMedPubMedCentral

16.

Cha SY, Choi YH, Hwang S, Jeong JY, An HJ (2017) Clinical impact of microRNAs associated with cancer stem cells as a prognostic factor in ovarian carcinoma. J Cancer 8(17):3538–3547. https://doi.org/10.7150/jca.20348 CrossRefPubMedPubMedCentral

17.

Ye Z, Li ZH, He SZ (2017) miRNA-1273g-3p involvement in development of diabetic retinopathy by modulating the autophagy-lysosome pathway. Med Sci Monit 23:5744–5751CrossRef

18.

Balkwill F (2002) Tumor necrosis factor or tumor promoting factor? Cytokine Growth Factor Rev 13(2):135–141CrossRef

19.

Kwong J, Chan FL, Wong KK, Birrer MJ, Archibald KM, Balkwill FR, Berkowitz RS, Mok SC (2009) Inflammatory cytokine tumor necrosis factor alpha confers precancerous phenotype in an organoid model of normal human ovarian surface epithelial cells. Neoplasia 11(6):529–541CrossRef

20.

Naylor MS, Stamp GW, Foulkes WD, Eccles D, Balkwill FR (1993) Tumor necrosis factor and its receptors in human ovarian cancer. Potential role in disease progression. J Clin Invest 91(5):2194–2206. https://doi.org/10.1172/JCI116446 CrossRefPubMedPubMedCentral

21.

Mori K, Hatamochi A, Ueki H, Olsen A, Jimenez SA (1996) The transcription of human alpha 1(I) procollagen gene (COL1A1) is suppressed by tumour necrosis factor-alpha through proximal short promoter elements: evidence for suppression mechanisms mediated by two nuclear-factor binding sites. Biochem J 319(Pt 3):811–816CrossRef

22.

Li AQ, Si JM, Shang Y, Gan LH, Guo L, Zhou TH (2010) Construction of COL1A1 short hairpin RNA vector and its effect on cell proliferation and migration of gastric cancer cells. Zhejiang Da Xue Xue Bao Yi Xue Ban 39(3):257–263PubMed

23.

Zeller C, Dai W, Steele NL, Siddiq A, Walley AJ, Wilhelm-Benartzi CS, Rizzo S, van der Zee A, Plumb JA, Brown R (2012) Candidate DNA methylation drivers of acquired cisplatin resistance in ovarian cancer identified by methylome and expression profiling. Oncogene 31(42):4567–4576. https://doi.org/10.1038/onc.2011.611 CrossRefPubMed

24.

Gifford G, Paul J, Vasey PA, Kaye SB, Brown R (2004) The acquisition of hMLH1 methylation in plasma DNA after chemotherapy predicts poor survival for ovarian cancer patients. Clin Cancer Res 10(13):4420–4426. https://doi.org/10.1158/1078-0432.CCR-03-0732 CrossRefPubMed

25.

Roy R, Yang J, Moses MA (2009) Matrix metalloproteinases as novel biomarkers and potential therapeutic targets in human cancer. J Clin Oncol 27(31):5287–5297. https://doi.org/10.1200/JCO.2009.23.5556 CrossRefPubMedPubMedCentral

26.

Zhang Y, Chen Q (2017) Relationship between matrix metalloproteinases and the occurrence and development of ovarian cancer. Braz J Med Biol Res 50(6):e6104. https://doi.org/10.1590/1414-431X20176104 CrossRefPubMedPubMedCentral

27.

Tholen S, Biniossek ML, Gansz M, Ahrens TD, Schlimpert M, Kizhakkedathu JN, Reinheckel T, Schilling O (2014) Double deficiency of cathepsins B and L results in massive secretome alterations and suggests a degradative cathepsin-MMP axis. Cell Mol Life Sci 71(5):899–916. https://doi.org/10.1007/s00018-013-1406-1 CrossRefPubMed

28.

Hijova E (2005) Matrix metalloproteinases: their biological functions and clinical implications. Bratisl Lek Listy 106(3):127–132PubMed

29.

Poon SL, Klausen C, Hammond GL, Leung PC (2011) 37-kDa laminin receptor precursor mediates GnRH-II-induced MMP-2 expression and invasiveness in ovarian cancer cells. Mol Endocrinol 25(2):327–338. https://doi.org/10.1210/me.2010-0334 CrossRefPubMed

30.

Laios A, Mohamed BM, Kelly L, Flavin R, Finn S, McEvoy L, Gallagher M, Martin C, Sheils O, Ring M, Davies A, Lawson M, Gleeson N, D’Arcy T, d’Adhemar C, Norris L, Langhe R, Saadeh FA, O’Leary JJ, O’Toole SA (2013) Pre-Treatment of platinum resistant ovarian cancer cells with an MMP-9/MMP-2 inhibitor prior to cisplatin enhances cytotoxicity as determined by high content screening. Int J Mol Sci 14(1):2085–2103. https://doi.org/10.3390/ijms14012085 CrossRefPubMedPubMedCentral

Titel: Potential biomarker of circulating hsa-miR-1273g-3p level for detection of recurrent epithelial ovarian cancer
verfasst von: Tuba Günel
Ece Gumusoglu
Berkcan Dogan
Fatma Betül Ertem
Mohammad Kazem Hosseini
Nazife Cevik
Taylan Senol
Samet Topuz
Kilic Aydinli
Publikationsdatum: 27.09.2018
Verlag: Springer Berlin Heidelberg
Erschienen in: Archives of Gynecology and Obstetrics / Ausgabe 6/2018
Print ISSN: 0932-0067
Elektronische ISSN: 1432-0711
DOI: https://doi.org/10.1007/s00404-018-4913-3

Neu im Fachgebiet Gynäkologie und Geburtshilfe

16.04.2024 | Maligne primäre ZNS-Tumoren | Nachrichten

Update Gynäkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert – ganz bequem per eMail.

Newsletter bestellen

Springer Medizin

Potential biomarker of circulating hsa-miR-1273g-3p level for detection of recurrent epithelial ovarian cancer

Abstract

Purpose

Methods

Results

Conclusion

Neu im Fachgebiet Gynäkologie und Geburtshilfe

Manche Gestagene können das Risiko für Meningeome erhöhen

Stillende Frauen haben geringeres kardiovaskuläres Risiko

Chronische Schmerzen nach Op. oft mit neuropathischer Komponente

Das Ende der vollständigen axillären Lymphknotendissektion

Update Gynäkologie

Springer Medizin

Abstract

Purpose

Methods

Results

Conclusion

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 6/2018

More women gynecologists in Belgium: assessment of changes in the workforce—a survey

Reply to letter to the editor

Disadvantages of a weight estimation formula for macrosomic fetuses: the Hart formula from a clinical perspective

Pathologies of the ischio-anal fossa: of gynaecological relevance?

Effect of intrauterine injection of human chorionic gonadotropin before fresh embryo transfer on IVF and ICSI outcomes: a meta-analysis

Indication of prophylactic vaccines as a tool for secondary prevention in HPV-linked disease

Neu im Fachgebiet Gynäkologie und Geburtshilfe

Manche Gestagene können das Risiko für Meningeome erhöhen

Stillende Frauen haben geringeres kardiovaskuläres Risiko

Chronische Schmerzen nach Op. oft mit neuropathischer Komponente

Das Ende der vollständigen axillären Lymphknotendissektion

Update Gynäkologie